The federal government can’t require AstraZeneca to change its policy on lowering drug prices for certain pharmacies used by health care facilities with low-income patients, a District of Delaware court determined Wednesday.

The opinion written by U.S. District Judge Leonard P. Stark remands a letter of violation in which the Health Resources and Services Administration claimed the drug manufacturer is legally held to charging lowered prices at any pharmacy contracted by an entity covered under the 340B Program.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]